Piper Jaffray analyst JP McKim notes that Senator Susan Collins tweeted that Medicare will start covering Insulet's Omnipod, which he sees as an incremental win for the company but not exactly what he had expected. Specifically, CMS views Omnipod as a Part D which is what Insulet wanted but CMS does not require their Part D sponsors to include Omnipod on their formularies, McKim notes. While the Medicare door is ajar for Omnipod, the analyst believes it is not fully opened just yet as Insulet will now have to get on each plan sponsors formulary, a task that will take further time and resources. He reiterates an Overweight rating and $65 price target on the shares.